Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, low concentrations of DMSO were found to decrease androgen receptor expression and inhibit the migration of prostate cancer cells, suggesting potential as an anticancer therapy.

This study investigated the metabolic pathways of epristeride, a new Type II 5α‐reductase inhibitor, using in vitro models and found that its metabolites show significant interactions with key proteins, suggesting implications for its role in doping control.

This article reviews updates on 5 alpha-reductase inhibitors for treating male pattern hair loss and presents no new clinical findings; the author aims to enhance understanding of these therapies.

In this study, researchers found that DNMT1-mediated methylation of SRD5A2 in urethral epithelial cells from hypospadias-afflicted rats upregulates proteins associated with cell cycle and mitochondrial function, suggesting SRD5A2 as a potential therapeutic target for hypospadias due to its role in modulating cellular functions.

In this study, no significant change in androgen receptor gene expression was found in females with recurrent spontaneous abortion, but a mutant genotype may offer some protection against the condition.

This consensus summary suggests that 5-alpha reductase inhibitors have clear benefits for benign prostatic hyperplasia, but their impact on prostate cancer prevention is still debated.

This study found that Medicare patients with benign prostatic hyperplasia had high adherence to 5-alpha reductase inhibitor therapy, which was associated with a reduced risk of needing surgical intervention.

In this research, Sertoli cell line model ST38c demonstrated that the androgen receptor regulates hormone pathways through specific coregulators, suggesting roles for SRC-2 and HBO1 in testicular development and androgen responsiveness.

This article from BJU International discusses the slow progress in prostate cancer research and reports no new findings.

This study suggests that inhibiting 5α-reductase activity alone, particularly with the type 1 inhibitor MK386, may not effectively reduce sebocyte activity or improve acne.

This meta-analysis reports that 5-alpha-reductase inhibitors are associated with a 31% increased risk of depression, with varying outcomes depending on the comparator group, highlighting significant heterogeneity across studies.

This review examines the use of 5-alpha-reductase inhibitors for treating benign prostatic hyperplasia, noting moderate positive effects without complete cure and the need for further research to understand drug mechanisms and pathogenesis.

This study concludes that high skin 5α-reductase activity may contribute to hirsutism, but the specific regulatory mechanisms and genetic factors remain unclear.

This case report suggests a potential link between the intake of Serenoa repens, commonly known as Saw palmetto, and the onset of erectile dysfunction.

The literature review concluded that while 5α-reductase inhibitors hold promise for managing prostate cancer, they raise significant safety concerns regarding their association with high-grade tumors and mortality, highlighting the need for careful consideration in their clinical use.

In this study, 4-(4-(phenylaminocarbonyl)benzoyl) benzoic acid exhibited the strongest inhibitory activity against the human type 2 steroid 5α-reductase isozyme among the compounds tested.

This study demonstrated that derivatives of dehydroepiandrosterone (2a-b, 3a-f, and 4a-f) significantly reduced viable LNCaP prostate cancer cells, suggesting potential therapeutic use for metastatic prostate cancer, while finasteride did not alter cell viability.

In this study, researchers identified and examined males with 17 beta-HSD3 deficiency in a highly inbred Arab population, noting genetic findings and the progression of male characteristics despite being raised as females initially.

This study found that among 17 beta-(N-ureylene-N,N'-disubstituted)-4-azasteroids, those with an N'-phenyl moiety were the most effective inhibitors of human type I 5 alpha-reductase.

In this study, pre-treatment with 5-α-reductase inhibitors (finasteride/dutasteride) in patients with metastatic renal cell carcinoma was associated with better immune checkpoint inhibitor effectiveness and improved progression-free and overall survival, without increasing severe side effects.

This study found that finasteride competitively inhibits the enzyme AKR1D1 with low micromolar affinity but does not act as a mechanism-based inactivator.

This study observed that the compound EM-402 reduced 5α-reductase activity and sebaceous gland size in the flank organs and ears of hamsters, indicating potent localized anti-androgenic effects without systemic action.

This study identified that methylation of the 5-AR2 gene promoter is linked to reduced expression of 5-AR2 protein, which may explain why some BPH patients are resistant to finasteride treatment.

This article discusses the role of the androgen receptor in regulating development and homeostasis, and reviews treatment approaches for conditions related to hormone imbalances, without reporting new clinical findings.

This study found that psychiatric adverse drug reactions were more frequently reported with finasteride than with dutasteride, but it remains unclear if there is a causal relationship.

This study found that both a proprietary ultrahigh-pressure extract and a hexanic extract of saw palmetto showed comparable inhibition of 5α-reductase, suggesting similar potential for managing symptoms of benign prostatic hyperplasia.

This commentary discusses how recent shifts in prostate cancer screening and management may render 5-alpha reductase inhibitors irrelevant for chemoprevention, despite evidence of their long-term safety and effectiveness in preventing low-grade prostate cancer.

This review discusses the potential of phytochemicals from plants as alternative treatments for prostate cancer, highlighting their possible benefits over current 5-alpha-Reductase inhibitors, but reports no new findings.

This study found that androgen metabolism within hair follicles varies significantly between compartments, with dermal papillae showing high 5α-reductase activity, suggesting a key role in androgen-driven hair growth responses.

Taking medication for hair loss might cause sexual problems.